Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy
Sarah Spiegel, Sheldon Milstien, Steven Grant
Oncogene (2011) Vol. 31, Iss. 5, pp. 537-551
Open Access | Times Cited: 138

Showing 26-50 of 138 citing articles:

Retracted: HDAC1 inhibition by melatonin leads to suppression of lung adenocarcinoma cells via induction of oxidative stress and activation of apoptotic pathways
Chongxi Fan, Yunhu Pan, Yang Yang, et al.
Journal of Pineal Research (2015) Vol. 59, Iss. 3, pp. 321-333
Closed Access | Times Cited: 58
Trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and promotes apoptosis of esophageal squamous cell lines
Junfen Ma, Xiaobing Guo, Shijie Zhang, et al.
Molecular Medicine Reports (2015) Vol. 11, Iss. 6, pp. 4525-4531
Open Access | Times Cited: 50
Maternal exposure to perfluorooctanoic acid (PFOA) causes liver toxicity through PPAR-α pathway and lowered histone acetylation in female offspring mice
Danyang Li, Linchao Zhang, Yan Zhang, et al.
Environmental Science and Pollution Research (2019) Vol. 26, Iss. 18, pp. 18866-18875
Closed Access | Times Cited: 50
Influenza A Virus Dysregulates Host Histone Deacetylase 1 That Inhibits Viral Infection in Lung Epithelial Cells
Prashanth Thevkar Nagesh, Matloob Husain
Journal of Virology (2016) Vol. 90, Iss. 9, pp. 4614-4625
Open Access | Times Cited: 48
Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines
Jan J. Bandolik, Alexandra Hamacher, Christian Schrenk, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 12, pp. 3052-3052
Open Access | Times Cited: 46
Discovery of Highly Selective and Potent HDAC3 Inhibitors Based on a 2-Substituted Benzamide Zinc Binding Group
Jian Liu, Younong Yu, Joseph Kelly, et al.
ACS Medicinal Chemistry Letters (2020) Vol. 11, Iss. 12, pp. 2476-2483
Open Access | Times Cited: 43
Therapeutic potential of CKD-506, a novel selective histone deacetylase 6 inhibitor, in a murine model of rheumatoid arthritis
Jin Kyun Park, Yu Jin Jang, Bo Ram Oh, et al.
Arthritis Research & Therapy (2020) Vol. 22, Iss. 1
Open Access | Times Cited: 42
Molecular Hallmarks of Adult T Cell Leukemia
Makoto Yamagishi, Toshiki Watanabe
Frontiers in Microbiology (2012) Vol. 3
Open Access | Times Cited: 57
Toxicological and metabolic considerations for histone deacetylase inhibitors
Joanna Fraczek, Tamara Vanhaecke, Vera Rogiers
Expert Opinion on Drug Metabolism & Toxicology (2013) Vol. 9, Iss. 4, pp. 441-457
Closed Access | Times Cited: 49
ST7612AA1, a Thioacetate-ω(γ-lactam carboxamide) Derivative Selected from a Novel Generation of Oral HDAC Inhibitors
Giuseppe Giannini, Loredana Vesci, Gianfranco Battistuzzi, et al.
Journal of Medicinal Chemistry (2014) Vol. 57, Iss. 20, pp. 8358-8377
Closed Access | Times Cited: 46
Role of Histone Deacetylases (HDACs) in Epilepsy and Epileptogenesis
Rita Citraro, Antonio Leo, Matteo Santoro, et al.
Current Pharmaceutical Design (2018) Vol. 23, Iss. 37, pp. 5546-5562
Open Access | Times Cited: 46
Manipulating macrophage polarization and function using classical HDAC inhibitors: Implications for autoimmunity and inflammation
Asadollah Mohammadi, A Amin Sharifi, Reza Pourpaknia, et al.
Critical Reviews in Oncology/Hematology (2018) Vol. 128, pp. 1-18
Closed Access | Times Cited: 46
Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities
Andrea Newbold, Geoffrey M. Matthews, Michael Bots, et al.
Molecular Cancer Therapeutics (2013) Vol. 12, Iss. 12, pp. 2709-2721
Open Access | Times Cited: 45
Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 – 2013)
Sérgio Valente, Antonello Mai
Expert Opinion on Therapeutic Patents (2014) Vol. 24, Iss. 4, pp. 401-415
Closed Access | Times Cited: 44
Aurora-B and HDAC synergistically regulate survival and proliferation of lymphoma cell via AKT, mTOR and Notch pathways
Chong Wang, Jing Chen, Weijie Cao, et al.
European Journal of Pharmacology (2015) Vol. 779, pp. 1-7
Closed Access | Times Cited: 43
PI3K/mTOR mediate mitogen-dependent HDAC1 phosphorylation in breast cancer: a novel regulation of estrogen receptor expression
Simona Citro, Claudia Miccolo, Laura Meloni, et al.
Journal of Molecular Cell Biology (2015) Vol. 7, Iss. 2, pp. 132-142
Open Access | Times Cited: 42
Histone deacetylases modulate resistance to the therapy in lung cancer
Estefanía Contreras-Sanzón, Heriberto Prado-Garcı́a, Susana Romero-García, et al.
Frontiers in Genetics (2022) Vol. 13
Open Access | Times Cited: 21
Benzothiazole derivatives as histone deacetylase inhibitors for the treatment of autosomal dominant polycystic kidney disease
Xudong Cao, Zhiyuan Fan, Lingfang Xu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 271, pp. 116428-116428
Closed Access | Times Cited: 4
VIPAS39 confers ferroptosis resistance in epithelial ovarian cancer through exporting ACSL4
Yuening Jiang, Jie Li, Tianzhen Wang, et al.
EBioMedicine (2025) Vol. 114, pp. 105646-105646
Closed Access
Distribution, Metabolism, and Excretion of [14C] Purinostat Mesylate, a Novel Selective HDAC I/IIb Inhibitor, in Rats Analyzed by High-Performance Liquid Chromatography coupled with LTQ Orbitrap Mass Spectrometry/Radioactivity Monitoring
Ziyan Ma, Minghai Tang, Linyu Yang, et al.
Journal of Pharmaceutical and Biomedical Analysis (2025), pp. 116834-116834
Closed Access
Histone deacetylases and their inhibitors: molecular mechanisms and therapeutic implications in diabetes mellitus
Xiaojie Wang, Xinbing Wei, Qi Pang, et al.
Acta Pharmaceutica Sinica B (2012) Vol. 2, Iss. 4, pp. 387-395
Open Access | Times Cited: 45
Inhibition of HDAC2 Protects the Retina From Ischemic Injury
Jie Fan, Oday Alsarraf, Mohammad Dahrouj, et al.
Investigative Ophthalmology & Visual Science (2013) Vol. 54, Iss. 6, pp. 4072-4072
Open Access | Times Cited: 44
Histone deacetylase (HDAC) inhibitors and regulation of TRAIL-induced apoptosis
Simone Fulda
Experimental Cell Research (2012) Vol. 318, Iss. 11, pp. 1208-1212
Closed Access | Times Cited: 44
A role for paralog-specific sumoylation in histone deacetylase 1 stability
Simona Citro, Ellis Jaffray, Ronald T. Hay, et al.
Journal of Molecular Cell Biology (2013) Vol. 5, Iss. 6, pp. 416-427
Open Access | Times Cited: 43
HDAC Inhibitors and Chaperone Function
Rekha Rao, Warren Fiskus, Siddhartha Ganguly, et al.
Advances in cancer research (2012), pp. 239-262
Closed Access | Times Cited: 42

Scroll to top